Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Accounting

Advertising

Consulting

Legal

Office

Officer and director remuneration

Patent fees

Depreciation

Directors Fees

Taxes

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Sunshine Biopharma

Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. Its products include treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Pointe-Claire, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter report. The Report shows gross revenues of $4,894,053 as of March 31, 2023, an increase of more than 2,100% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October 2022.

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

MONTREAL, April 05, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights.

Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update

MONTREAL, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of an exclusive worldwide license agreement (the “License Agreement”) with the University of Arizona. The License Agreement grants Sunshine Biopharma exclusive worldwide rights for all of the University of Arizona and University of Illinois Chicago technology pertaining to PLpro protease inhibitors of SARS-CoV-2, the coronavirus that causes COVID-19. Sunshine Biopharma has been working on this project in collaboration with the University of Arizona since February 2022. The collaboration granted Sunshine Biopharma an exclusive option to obtain a license for the related technology.

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of a research agreement with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada. The research effort will be focused on advancing the development of Sunshine Biopharma's Adva-27a anticancer compound through the IND-enabling studies. At any time the research results become conclusive and Sunshine Biopharma wishes to proceed to conducting a Phase I clinical trial, the Jewish General Hospital is prepared to negotiating a new agreement to define the responsibilities and obligations of the parties for such Phase I clinical trial to be performed.

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company's common stock.

Sunshine Biopharma Announces Share Repurchase Program

MONTREAL, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today issued a letter to shareholders from Dr. Steve Slilaty, Chairman and CEO of the Company.

Sunshine Biopharma's Annual Letter to Shareholders

Regional Management

Credit Acceptance

West Fraser Timber Co. Ltd.

As investors prepare for the holiday season, GuruFocus' value screeners identified several stocks that meet screening criteria based on key principles taught by Benjamin Graham, Peter Lynch and Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial) co-managers Warren Buffett (Trades, Portfolio) and Charlie Munger (Trades, Portfolio). Four stocks that meet such criteria are Sunshine Biopharma Inc. ( SBFM , Financial), Regional Management Corp. ( RM , Financial), West Fraser Timber Co. Ltd.

4 Stocks Meeting GuruFocus' Value Screens in December

MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of North America's leading lipid nanoparticle (“LNP”) companies. The purpose of the collaboration is to advance the development of Sunshine Biopharma's mRNA-based anticancer macromolecule, K1.1.

Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project

MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. As such, Nora Pharma Inc. is now a wholly owned subsidiary of Sunshine Biopharma Inc.

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Company Reports Significant Increase in Cash on Hand as a Result of Recent Financings Company Reports Significant Increase in Cash on Hand as a Result of Recent Financings

Sunshine Biopharma Files Its Second Quarter Report With the SEC

MONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has agreed to provide additional resources to the University of Arizona R. Ken Coit College of Pharmacy for the purposes of accelerating the development of novel PLpro inhibitors currently underway. The development of the Company's lead PLpro inhibitor, SBFM-PL4, is continuing in parallel.

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

CytoSorbents

Standard BioTools Inc

ReWalk Robotics

Troika Media Group

Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy In June According To These Insiders Part 1

Investors with a very high appetite for risk and seeking ultra-high-growth stocks can find potential opportunities within the pharma and biotech domain. Investing in development-stage biopharma companies is a typical high-risk, high-return bet that can end up providing multi-bagger returns if the company's research is successful.

Sunshine Biopharma: An Opportunity Knocking?

MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announced private placement pursuant to a securities purchase agreement entered into on April 25, 2022 with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

NEW YORK, NY / ACCESSWIRE / April 28, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ:SBFM) About Sunshine Biopharma, Inc. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness.

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

SBFM stock is trading at a surprisingly low price, considering Sunshine Biopharma's demonstrably positive clinical results. The post Multiple Promising Treatments Accentuate the Bull Case for Sunshine Biopharma appeared first on InvestorPlace.

Multiple Promising Treatments Accentuate the Bull Case for Sunshine Biopharma

MONTREAL, April 26, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it entered into a securities purchase agreement with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Today, investors in Sunshine Biopharma and SBFM stock are getting a huge boost from news that the company filed a patent for a key drug. The post Why Is Sunshine Biopharma (SBFM) Stock Up Today?

Why Is Sunshine Biopharma (SBFM) Stock Up Today?

Sunshine Biopharma Inc (NASDAQ: SBFM) shares are trading higher Monday after the company announced it filed a United States provisional patent application covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in.

Why Sunshine Biopharma Stock Is Surging

MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.

Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells

An SEC filing may have deterred some traders from holding SBFM stock. However, a closer look at the facts should clear up any confusion.

Blockbuster Clinical Results Shine a Positive Light on Sunshine Biopharma

Diffusion Pharmaceuticals

Lion Group Holding

Sono Group NV

Tuscan Holdings Corp II

A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to the markets.

5 Stocks Halted In Tuesday's Session

Sunshine Biopharma's winning streak is likely finished due to confusion over an announcement. Here's why SBFM stock is down today.

Why Is Sunshine Biopharma (SBFM) Stock Down 30% Today?

Sunshine Biopharma Inc (NASDAQ: SBFM) shares are trading lower Friday morning after the company announced a common stock offering.  Sunshine Biopharma plans to offer on a resale basis an aggregate of 7,207,208 shares of common stock.

Why Sunshine Biopharma Stock Is Falling Today

Sunshine Biopharma Inc (NASDAQ: SBFM) is trading higher Wednesday on continued momentum after the company on Tuesday announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture. Toxicity studies using non-transformed human cells showed that.

News for Sunshine Biopharma Stock (SBFM)